Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Yang, Chunmei ^a   Lee, Heehyoung ^a   Jove, Veronica ^a   Deng, Jiehui ^a   Zhang, Wang ^a   Liu, Xueli ^a   Forman, Stephen ^a   Dellinger, Thanh H ^a   Wakabayashi, Mark ^a   Yu, Hua ^a   Pal, Sumanta ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER PROGNOSIS; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPHOCYTIC INFILTRATION; OVARY CANCER; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STAT3 TRANSCRIPTION FACTOR;

EID: 84872229121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054029     Document Type: Article

References (33)

1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine 348: 203-213.
2. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G, (2012) Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124: 192-198.
3. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, et al. (2009) Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 115: 2891-2902.
4. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, et al. (2008) Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14: 7667-7673.
5. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, et al. (2009) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22: 393-402.
6. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104: 3360-3365.
7. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, et al. (2008) HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14: 3372-3379.
8. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, et al. (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58: 449-459.
9. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
10. Stumpf M, Hasenburg A, Riener MO, Jutting U, Wang C, et al. (2009) Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 101: 1513-1521.
11. Tomsova M, Melichar B, Sedlakova I, Steiner I, (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108: 415-420.
12. Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, et al. (2010) Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 116: 556-562.
13. Fialova A, Partlova S, Sojka L, Hromadkova H, Brtnicky T, et al. (2012) Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer.
14. Nelson BH, (2010) CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes. The Journal of Immunology 185: 4977-4982.
15. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, et al. (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117: 574-586.
16. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, et al. (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48: 541-549.
17. Qin Z, Richter G, Schuler T, Ibe S, Cao X, et al. (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4: 627-630.
18. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, et al. (2009) Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS ONE 4: e6412.
19. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321.
20. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54.
21. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, et al. (1995) Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1: 501-507.
22. Ikarashi H, Fujita K, Takakuwa K, Kodama S, Tokunaga A, et al. (1994) Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res 54: 190-196.
23. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, et al. (1991) Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51: 1934-1939.
24. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, et al. (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118: 3367-3377.
25. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321.
26. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, et al. (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27: 925-932.
27. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43.
28. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
29. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789-796.
30. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, et al. (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4: e6412.
31. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, et al. (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376: 1155-1163.
32. Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, et al. (2010) Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer 46: 170-179.
33. Rustin GJS, van der Burg MEL, Griffin CL, Guthrie D, Lamont A, et al. (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet 376: 1155-1163.